Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has been approved by the European Commission (EC). The ...

Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's ...

It was a busy week for the biotech sector as usual, with lots of regulatory and pipeline updates, before the first-quarter ...

CHMP reversed its initial recommendation for the EC to not authorize the drug due to the risk of side effects like ARIA.

The European Commission said Wednesday that it had given formal approval for Leqembi, a long-awaited new treatment for ...